Nasal Therapeutics

Nasal Therapeutics, Inc. is a biotechnology company founded in 2007 by Dr. Charles Hensley, the inventor of the Zicam cold remedy. The company focuses on the development of intranasal drug delivery systems and therapeutics for a variety of conditions, including migraines, the common cold, and allergies. Its core technology is based on a platform targeting excitatory amino acid (EAA) transport proteins, which the company believes play a role in neurodegenerative diseases and migraine pathophysiology. Nasal Therapeutics has historically marketed homeopathic nasal sprays such as Theramax and developed the migraine treatment Migranade. While the company was active in the late 2000s and has been cited in recent market reports regarding GLP-1 nasal delivery, its current operational status is unclear and it is largely associated with its founder's historical ventures.